There are even those patients whose problem lies somewhere between these three disorders viagra australia is the most popular in Australia, followed by vardenafil and tadalafil as active ingredients.

Labaton.com

UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY
IN RE SCHERING-PLOUGH Civil Action No. 08-397 (DMC) (JAD) CORPORATION / ENHANCE SECURITIES LITIGATION NOTICE OF PENDENCY OF CLASS ACTION
All persons and entities that purchased or acquired Schering-Plough Corporation ("Schering") common stock, 6% mandatory convertible preferred stock maturing August 13, 2010 ("Preferred Stock"), or call options, and/or sold Schering put options, during the period between January 3, 2007 through and including March 28, 2008 (the "Class Period"), and who did not sell their stock and/or options on or before December 11, 2007, and who were damaged thereby (the "Class"). A federal court has authorized this notice. This is not a solicitation from a lawyer.
PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY.
YOUR RIGHTS WILL BE AFFECTED BY A CLASS ACTION LAWSUIT
PENDING IN THIS COURT.
This Notice is being sent pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the District of New Jersey (the "Court") to inform you of a class action lawsuit that is now pending in the Court under the above caption (the "Action") against Schering, Merck/Schering-Plough Pharmaceuticals ("M/S-P"), Fred Hassan, Carrie S. Cox, Robert J. Bertolini, Steven H. Koehler, Susan Ellen Wolf, the Director Defendants1, and the Underwriter Defendants2 (collectively, the "Defendants"), and that the Action has been certified by the Court to proceed as a class action on behalf of the Class of certain purchasers and acquirors of Schering common stock, Preferred Stock or call options and certain sellers of Schering put options.
1. The "Class," as certified by the Court, consists of: All persons and entities that purchased or acquired Schering common stock, 6% mandatory convertible preferred stock maturing August 13, 2010, or call options, and/or sold Schering put options, during the period between January 3, 2007 through and including March 28, 2008, and who did not sell their stock and/or options on or before December 11, 2007, and who were damaged thereby.
Excluded from the Class by definition are: (a) Defendants; (b) members of the immediate families of the Individual Defendants; (c) the subsidiaries and affiliates of Defendants; (d) any person or entity who was a partner, executive officer, director, or controlling person of Schering, M/S-P or Merck & Co., Inc. ("Merck") (including any of their subsidiaries or affiliates), or any other Defendants; (e) any entity in which any Defendant has a controlling interest; (f) Defendants' directors' and officers' liability insurance carriers, and any affiliates or subsidiaries thereof; and (g) the legal representatives, heirs, successors and assigns of any such excluded party.
2. This Notice is directed to you because you may be a member of the Class. If you are a member of the Class, your rights will be affected by this Action. If you do not meet the Class definition, this Notice does not apply to you. If you are uncertain whether you are a member of the Class, contact Class Counsel listed in paragraph 23 below, or your own 1 The "Director Defendants" are Hans W. Becherer, Thomas J. Colligan, C. Robert Kidder, Philip Leder, M.D., Eugene R. McGrath, Carl E. Mundy, Jr., Antonio M. Perez, Patricia F. Russo, Jack L. Stahl, Kathryn C. Turner, Robert F.W. van Oordt, and Arthur F. Weinbach.
2 The "Underwriter Defendants" are ABN AMRO Rothschild LLC, Banc of America Securities LLC, Banca IMI SpA, BBVA Securities Inc., Bear, Stearns & Co. Inc. (now J.P. Morgan Securities LLC), BNP Paribas Securities Corp., BNY Capital Markets, Inc., Citigroup Global Markets, Inc., Credit Suisse Securities (USA) LLC, Daiwa Capital Markets America Inc., Goldman, Sachs & Co., ING Financial Markets LLC, J.P. Morgan Securities LLC, Mizuho Securities USA Inc., Morgan Stanley & Co. LLC, Santander Investment Securities Inc., Utendahl Capital Partners, L.P., and The Williams Capital Group L.P.
K8951 v.07 01.10.2013 3. This Notice is not an admission by Defendants or an expression of any opinion of the Court concerning the merits of the Action, or a finding by the Court that the claims asserted by Lead Plaintiffs (defined below in paragraph 8) in this case are valid. This Notice is intended solely to advise you of the pendency of the Action and of your rights in connection with it. There is no settlement or monetary recovery at this time. Defendants have denied Lead Plaintiffs' claims and contend that they are not liable for the harm alleged by Lead Plaintiffs.
4. The Class definition may be subject to change by the Court pursuant to Rule 23 of the Federal Rules of Civil Procedure.
OVERVIEW AND STATUS OF THIS ACTION 5. Vytorin is a cholesterol-lowering medication that is a combination of two drugs – Zocor (simvastatin), developed by Merck, and Zetia (ezetimibe), developed by Schering. During the Class Period, Vytorin was marketed by M/S-P, a joint venture of Merck and Schering. Beginning in 2004, Merck and Schering undertook a clinical trial, known as the ENHANCE study, to test whether the combination of Zocor and Zetia in Vytorin was more effective than Zocor alone in preventing the progression of atherosclerosis (plaque buildup in the arteries). In January 2008, M/S-P issued a news release announcing certain top-line results of the ENHANCE study. In March 2008, the complete ENHANCE results were published in the New England Journal of Medicine and presented at the American College of Cardiology 6. The initial complaint in this Action was filed in January 2008.
7. By Order dated March 3, 2008, the Court ordered that any related securities actions filed in, removed to or transferred to the District of New Jersey be consolidated with this Action. On March 27, 2008, a related securities action, Kamel v. Schering-Plough Corp., et al., Civil Action No. 08-1000 (DMC), was consolidated with the Action for all purposes.3 8. On April 18, 2008, the Court entered an Order appointing the Arkansas Teacher Retirement System, the Public Employees' Retirement System of Mississippi, the Louisiana Municipal Police Employees' Retirement System, and the Massachusetts Pension Reserves Investment Management Board (collectively, "Lead Plaintiffs") as Lead Plaintiffs for the Action pursuant to the Private Securities Litigation Reform Act of 1995. In the same Order, the Court approved Lead Plaintiffs' selection of Bernstein Litowitz Berger & Grossmann LLP and Labaton Sucharow LLP as Co-Lead Counsel for the Class and approved Lead Plaintiffs' selection of Carella, Byrne, Cecchi, Olstein, Brody & Agnello, PC as Liaison Counsel for the Class.
9. On September 15, 2008, Lead Plaintiffs filed their Consolidated Class Action Complaint for Violations of the Federal Securities Laws (the "Complaint"), asserting claims under Sections 10(b), 20(a) and 20A of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, and Sections 11, 12(a), 15 of the Securities Act of 1933 (the "Securities Act"). The Complaint alleges that Schering, M/S-P, and certain of Schering's officers made false or misleading statements or omissions about the efficacy and commercial prospects of Vytorin and Zetia, including by intentionally withholding the results of the ENHANCE study. The Complaint alleges that these false statements and omissions caused the price of Schering common stock, Preferred Stock and call options to be artificially inflated and the price of Schering put options to be artificially depressed during the Class Period and that the price of Schering common stock, Preferred Stock and call options declined and the price of Schering put options increased when the truth about the ENHANCE study was disclosed. The Complaint also alleges that Cox violated federal securities laws against insider trading because Cox sold Schering common stock while in possession of material, non-public information. The Complaint further alleges that Schering, Hassan, Bertolini, Koehler, Wolf, the Director Defendants, and Underwriter Defendants are statutorily responsible for false or misleading statements made in offering documents in connection with an August 9, 2007 offering of Schering common stock and/or an August 15, 2007 offering of Schering Preferred Stock.
10. Defendants moved to dismiss the Complaint on December 10, 2008. On September 2, 2009, the Court issued an Opinion and entered an Order denying Defendants' motions to dismiss. 11. On September 17, 2009, Defendants moved for reconsideration of the Court's Opinion and Order denying Defendants' motions to dismiss. The motion for reconsideration was denied by the Court on June 21, 2010. 3 Separate securities fraud actions based on the same underlying factual allegations were also brought on behalf of purchasers of Merck securities against Merck, M/S-P, and certain of Merck's officers. These actions have been consolidated in In re Merck & Co., Inc. Vytorin / Zetia Securities Litigation, Civil Action No. 08-2177 (DMC)(JAD) (the "Merck Action"). The Merck Action has been certified as a class action on behalf of certain purchasers or acquirors of Merck common stock and call options and certain sellers of Merck put options and is the subject of a separate Notice of Pendency of Class Action being mailed to potential members of the class in that action.
K8952 v.07 01.10.2013 12. Defendants answered the Complaint on November 18, 2009. Defendants have denied any violations of the securities laws and asserted affirmative defenses to Lead Plaintiffs' allegations.
13. On February 7, 2011, Lead Plaintiffs filed their motion for class certification and, on September 22, 2011, filed an amended motion for class certification. Following class certification discovery, on September 25, 2012, the Court issued an Order and an Opinion granting Lead Plaintiffs' motion certifying the Class, appointing Lead Plaintiffs as Class Representatives and appointing Lead Counsel as Class Counsel. On October 11, 2012, the Court entered an Amended Order relating to the definition of the Class (the "Class Order"). 14. On March 1, 2012, Schering, M/S-P and the Individual Defendants moved for partial summary judgment contending, among other things, that the declines in Schering's common and Preferred Stock and option prices on certain dates were not caused by disclosure of the alleged fraud. The Underwriter Defendants also moved for summary judgment contending that they had conducted a reasonable investigation and thus satisfied the "due diligence" defense to liability under the Securities Act. The motions were fully briefed, and on September 25, 2012, the Court issued an Order denying both motions. 15. On October 9, 2012, Defendants filed two petitions in the United States Court of Appeals for the Third Circuit (the "Third Circuit") seeking leave to appeal the Court's rulings on class certification. On January 7, 2013, the Third Circuit denied those petitions.
16. The trial in this action has been scheduled by the Court to begin on March 4, 2013.
YOUR RIGHTS AS A CLASS MEMBER 17. A class action is a type of lawsuit in which one or several individuals or entities prosecute claims on behalf of all members of a group of similarly-situated persons and entities to obtain monetary or other relief for the benefit of the entire group. Class actions avoid the necessity of each member of a class having to file his, her or its own separate lawsuit to obtain relief. Class actions are used to decide legal and factual issues that are common to all members of a class.
18. If you purchased or acquired Schering common stock, Preferred Stock or call options and/or sold Schering put options during the period between January 3, 2007 through and including March 28, 2008, did not sell all of these stocks and/ or options on or before December 11, 2007, and were damaged thereby, and you are not excluded from the Class by definition, you are a member of the Class. If you are a member of the Class, you have the right to decide whether to remain a member of the Class. If you choose to remain a member of the Class, you do not need to do anything at this
time other than to retain your documentation reflecting your transactions in Schering common stock and Preferred
Stock and options on Schering common stock as discussed below in paragraph 19. If you are a member of the Class
and wish to be excluded from the Class, you must request exclusion in accordance with the procedure set forth in paragraph 20, below. Your decision is important for the following reasons: a. If you choose to remain a member of the Class, you will be bound by all past, present and future orders and
judgments in the Action, whether favorable or unfavorable. If any money is awarded to the Class, either through a settlement with Defendants or a judgment of the Court, you will be eligible to receive a share of that award. However, if you remain a member of the Class, you may not pursue a lawsuit on your own behalf with regard to any of the issues in this Action. Pursuant to Rule 23(e)(4) of the Federal Rules of Civil Procedure, it is within the Court's discretion whether to allow a second opportunity to request exclusion from the Class if there is a settlement or judgment in the Action. Please note that if you remain a member of the Class, you will not be personally responsible for Class Counsel's attorneys' fees or costs. Class Counsel have agreed to represent the Class on a contingent fee basis, which means that they will be awarded fees and costs only if they succeed in obtaining a recovery from one or more Defendants. Any attorneys' fees for Class Counsel will be awarded by the Court from the settlement or judgment, if any, obtained on behalf of the Class. As a member of the Class you will be represented by Class Counsel. You may remain a member of the Class and elect to be represented by counsel of your own choosing. If you do retain separate counsel, you will be responsible for those attorneys' fees and expenses and such counsel must enter an appearance on your behalf by filing a Notice of Appearance with the Court and mailing it to Class Counsel at the addresses set forth in paragraph 23 below on or before March 1, 2013.
b. If you choose to be excluded from the Class, you will not be bound by any judgment in this Action, nor will you
be eligible to share in any recovery that might be obtained in this Action. You will retain any right you have to individually pursue any legal rights that you may have against any Defendants with respect to the claims asserted in the Action. Please refer to paragraphs 20-22 below if you would like to be excluded from the Class.
19. Members of the Class will be eligible to participate in any recovery that might be obtained in the Action. While this K8953 v.07 01.10.2013 Notice is not intended to suggest any likelihood that Lead Plaintiffs or members of the Class will recover any such damages, should there be a recovery, members of the Class will be required to support their requests to participate in the distribution of any such recovery by demonstrating their membership in the Class and documenting their purchases and sales of Schering common stock, Preferred Stock and/or options on Schering common stock, and their resulting damages. For this reason, please be sure to keep all records of your transactions in these securities.
HOW TO BE EXCLUDED FROM THIS CLASS 20. If you wish to be excluded from the Class, you must specifically request exclusion in accordance with the following procedures. To exclude yourself from the Class, you must send a letter by first-class mail stating that you "request exclusion from the Class in In re Schering-Plough Corporation / ENHANCE Securities Litigation, Civil Action No. 08-397 (DMC) (JAD)." Your request must (i) state the name, address and telephone number of the person or entity requesting exclusion; (ii) state the number of shares of Schering common stock, Preferred Stock and call and put options on Schering common stock purchased, acquired and/or sold during the Class Period as well as the dates and prices of each such purchase, acquisition and/or sale; and (iii) be signed by the person or entity requesting exclusion or an authorized representative. You must mail your exclusion request, postmarked by no later than March 1, 2013, to:
In re Schering-Plough Corporation / ENHANCE Securities Litigation Portland, OR 97208-3127 You cannot exclude yourself from the Class by telephone or by e-mail and a request for exclusion shall not be effective unless it contains all the information called for by this paragraph and is postmarked by the date stated above, or is otherwise accepted by the Court.
21. If your request for exclusion complies with the requirements set forth above, you will not be bound by any judgment in this Action, nor will you be eligible to share in any recovery that might be obtained in this Action.
22. Do not request exclusion from the Class if you wish to participate in this Action as a member of the Class.
23. As a member of the Class, you will be represented by Class Counsel, who are: Salvatore J. Graziano Christopher J. McDonald LABATON SUCHAROW LLP
BERGER & GROSSMANN LLP
1285 Avenue of the Americas New York, NY 10005 New York, NY 10019 24. As noted above, unless you elect to retain your own personal lawyer, by remaining in the Class, you will not subject yourself to any direct obligations to pay the costs of the litigation. In the event there is a recovery by the Class in this Action, all costs and expenses of the Action, including Class Counsel's attorneys' fees, will be paid from that recovery in an amount approved by the Court.
K8954 v.07 01.10.2013 PLEASE KEEP YOUR ADDRESS CURRENT 25. To assist the Court and the parties in maintaining accurate lists of Class members, you are requested to mail notice of any changes in your address to: In re Schering-Plough Corporation / ENHANCE Securities Litigation Portland, OR 97208-3127 26. If this Notice was forwarded to you by the postal service, or if it was otherwise sent to you at an address that is not current, you should immediately contact the Administrator, Epiq Systems, Inc., at the address above or by calling 877-854-4458 and provide them with your correct address. If the Administrator does not have your correct address, you may not receive notice of important developments in this Action.
WHERE YOU CAN FIND ADDITIONAL INFORMATION 27. This Notice gives only a summary of the lawsuit and the claims asserted by Lead Plaintiffs. For more detailed information regarding the Action, you may contact Class Counsel or visit www.scheringvytorinsecuritieslitigation.com.
PLEASE DO NOT CALL OR WRITE THE COURT.
NOTICE TO SECURITY BROKERS AND OTHER NOMINEES 28. If, for the beneficial interest of any person or entity other than yourself, you purchased or acquired Schering common stock, Preferred Stock or call options and/or sold Schering put options during the period between January 3, 2007 through and including March 28, 2008, you must either (a) within seven (7) calendar days of receipt of this Notice, request from the Administrator sufficient copies of the Notice to forward to all such beneficial owners and within seven (7) calendar days of receipt of those Notices forward them to all such beneficial owners; or (b) within seven (7) calendar days of receipt of this Notice, provide a list of the names and addresses of all such beneficial owners to the Administrator at In re Schering-Plough Corporation / ENHANCE Securities Litigation, P.O. Box 3127, Portland, OR 97208-3127 or via email to info@scheringvytorinsecuritieslitigation.com. If you choose the first option, you must send a statement to the Administrator confirming that the mailing was made and you must retain your mailing records for use in connection with any further notices that may be provided in the Action. If you choose the second option, the Administrator will send a copy of the Notice to the beneficial owners. Upon full compliance with these directions, such nominees may seek reimbursement of their reasonable expenses actually incurred by providing the Administrator with proper documentation supporting the expenses for which reimbursement is sought.
Dated: January 17, 2013 BY ORDER OF THE COURT: United States District Court for the District of New Jersey K8955 v.07 01.10.2013

Source: http://www.labaton.com/en/cases/upload/Schering-Notice-of-Pendency.pdf

jewishmarbella.com.es

Issue No. 55 FOCUS 5767 . Primavera - Spring - 2007 The Journal of the Marbella Jewish Community La revista de la Comunidad Judia de Marbella Modern stacked glass sculptures among Sculptures de cristal amoncelees entre the ruins of the 2000 year old Herodian les ruines vieilles de 2000 ans du 2iem 2nd Temple of Jerusalem

coordinamentocsmlazio.it

Guideline Summary NGC-6421 Guideline T itle Use of psychiatric medications during pregnancy and lactation. American College of O bstetricians and Gynecologists (ACO G). Use of psychiatric medications during pregnancy andlactation. W ashington (DC): American College of O bstetricians and Gynecologists (ACO G); 2008 Apr. 20 p. (ACO G practicebulletin; no. 92). [245 references]